BE
Beam
BEAM·NASDAQCambridge MAFounded 2017500 employees
Mid CapbiotechPublicGenetic MedicineHematology
Platform: Base Editing
Market Cap
$2.5B
All Drugs
3
Clinical Trials
5
Failed / Terminated
0
FDA Approved
1
Stock Price & Catalysts (BEAM)
Loading BEAM stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| BEA-2615 | BEA-2615 | Phase 3 | 2 | PRMT5 | EpilepsyEwing Sarcoma | ||
| Zorizumab | BEA-3996 | Approved | 2 | CD123 | PAH | ||
| BEA-4274 | BEA-4274 | Phase 1/2 | 1 | ALK | Schizophrenia |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (5)